Evidence map›Paper›PMID 40279954›Full record

ArticleClinics (Sao Paulo, Brazil)2025

Inhibition of NSUN3 suppresses immune escape in non-small cell lung cancer through stabilizing PD-L1 in a 5-methyladenosine dependent way.

Hancong Huang, Xiaohong Lv, Qianhua Chen, Lixia Dong

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hancong HuangDepartment of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, PR China; Department of Respiratory and Critical Care Medicine, Aviation General Hospital, Beijing, PR China.
Xiaohong LvDepartment of Respiratory and Critical Care Medicine, Aviation General Hospital, Beijing, PR China.
Qianhua ChenDepartment of Respiratory and Critical Care Medicine, Aviation General Hospital, Beijing, PR China.
Lixia DongDepartment of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, PR China; Department of Respiratory and Critical Care Medicine, Aviation General Hospital, Beijing, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlterations in 5-methyladenosine (m

methodsNSUN3 expression levels in NSCLC tissues and cell lines were quantified using quantitative Reverse Transcription PCR (RT-qPCR). The impact of NSUN3 expression modulation on lung cancer cell viability and proliferation was assessed through CCK-8 assays and colony formation experiments. To evaluate immune cell interactions, CD8+ T-cells were co-cultured with NSCLC cells, and cytotoxic activity was measured by an LDH cytotoxicity detection kit. The in vivo tumorigenic role of NSUN3 was investigated using subcutaneous tumor xenograft models. Mechanistic insights into NSUN3-PD-L1 interactions were obtained through m

resultsElevated NSUN3 mRNA levels were observed in NSCLC tissues compared to normal controls. Functional studies demonstrated that NSUN3 knockdown significantly inhibited cell viability and proliferation in both A549 and PC9 cell lines. Furthermore, NSUN3 depletion enhanced CD8+ T-cell-mediated cytotoxicity against NSCLC cells and suppressed tumor growth in vivo. Mechanistically, NSUN3 inhibition was found to stabilize PD-L1 mRNA, suggesting a regulatory role in immune checkpoint modulation.

conclusionsThe present findings establish NSUN3 as an oncogenic driver in NSCLC pathogenesis, functioning through PD-L1 mRNA stabilization. The identification of this NSUN3-PD-L1 regulatory axis provides new insights into the molecular mechanisms underlying immune escape in NSCLC and offers promising directions for developing targeted immunotherapies.

Indexed as

AdenosineB7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsMethyltransferasesTumor EscapeAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansMiceAdenosineB7-H1 AntigenCD274 protein, humanMethyltransferasesN-methyladenosineCD8-positive T-lymphocytesNon-small cell lung cancerNSUN3Programmed Cell Death 1 ligand 1

Identifiers

PMID40279954
PMCPMC12060472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.